ICLR | ICON Public Limited Company

Index- P/E35.89 EPS (ttm)6.18 Insider Own4.00% Shs Outstand81.78M Perf Week0.22%
Market Cap17.72B Forward P/E15.27 EPS next Y14.54 Insider Trans0.00% Shs Float81.08M Perf Month15.66%
Income510.00M PEG2.63 EPS next Q3.08 Inst Own98.16% Short Float / Ratio1.47% / 1.90 Perf Quarter3.75%
Sales7.82B P/S2.27 EPS this Y172.30% Inst Trans0.92% Short Interest1.19M Perf Half Y12.72%
Book/sh105.81 P/B2.10 EPS next Y15.26% ROA3.00% Target Price250.69 Perf Year-3.74%
Cash/sh3.53 P/C62.94 EPS next 5Y13.67% ROE6.10% 52W Range171.43 - 249.62 Perf YTD14.25%
Dividend- P/FCF48.88 EPS past 5Y3.00% ROI5.60% 52W High-11.09% Beta1.11
Dividend %- Quick Ratio1.20 Sales past 5Y34.50% Gross Margin29.10% 52W Low29.46% ATR6.29
Employees41100 Current Ratio1.20 Sales Q/Q4.00% Oper. Margin10.80% RSI (14)61.46 Volatility2.45% 3.06%
OptionableYes Debt/Eq0.52 EPS Q/Q4.20% Profit Margin6.50% Rel Volume0.73 Prev Close225.06
ShortableYes LT Debt/Eq0.50 EarningsApr 26 AMC Payout0.00% Avg Volume629.29K Price221.93
Recom1.90 SMA204.74% SMA507.55% SMA2006.31% Volume456,960 Change-1.39%
Date Action Analyst Rating Change Price Target Change
Jan-17-23Upgrade Barclays Equal Weight → Overweight $215 → $260
Jan-13-23Upgrade Barclays Equal Weight → Overweight
Nov-09-22Upgrade BofA Securities Neutral → Buy $265 → $260
Sep-07-22Initiated UBS Buy $270
Aug-25-22Initiated Credit Suisse Neutral $260
May-24-22Initiated Guggenheim Buy $285
Apr-25-22Downgrade Wells Fargo Overweight → Equal Weight $250
Apr-12-22Upgrade Deutsche Bank Hold → Buy $234 → $310
Sep-27-21Upgrade JP Morgan Neutral → Overweight $230 → $320
Aug-05-21Resumed Credit Suisse Outperform $250
Jun-02-23 06:41PM
May-31-23 06:00AM
May-27-23 10:16AM
May-16-23 06:00AM
May-08-23 11:08AM
09:28PM Loading…
Apr-27-23 09:28PM
Apr-26-23 06:55PM
04:32PM
Apr-25-23 06:45PM
Mar-29-23 02:05PM
06:00AM
Mar-25-23 07:20AM
Mar-13-23 07:46AM
Mar-10-23 02:00AM
Feb-27-23 04:15PM
12:46PM Loading…
12:46PM
Feb-24-23 05:10AM
Feb-22-23 08:05PM
04:30PM
Feb-13-23 11:58PM
Feb-07-23 12:10PM
Feb-06-23 05:14PM
Jan-26-23 04:15PM
Jan-23-23 08:02AM
Jan-11-23 10:10AM
Jan-10-23 06:24PM
08:45AM
Jan-03-23 04:15PM
Dec-26-22 10:25PM
Dec-13-22 07:00AM
09:15AM Loading…
Dec-12-22 09:15AM
Nov-29-22 10:02AM
Nov-23-22 04:15PM
Nov-02-22 07:45PM
04:15PM
01:31PM
Oct-26-22 10:01AM
Oct-24-22 09:37AM
Oct-18-22 03:23PM
Oct-17-22 02:07PM
Oct-06-22 08:00AM
Sep-26-22 04:15PM
Sep-21-22 06:39AM
Sep-13-22 09:08AM
Sep-06-22 04:15PM
Aug-31-22 04:15PM
Aug-16-22 07:36AM
Aug-12-22 12:01PM
Aug-03-22 09:05AM
Aug-02-22 11:40AM
Jul-27-22 06:35PM
04:20PM
04:15PM
Jul-20-22 10:01AM
Jun-22-22 09:56AM
Jun-21-22 04:15PM
Jun-14-22 08:04AM
Jun-09-22 05:18PM
May-23-22 04:15PM
07:00AM
May-10-22 12:49PM
May-03-22 04:15PM
Apr-27-22 06:35PM
04:15PM
Apr-20-22 03:01PM
Apr-14-22 06:28AM
Mar-30-22 08:44AM
Mar-16-22 12:25PM
Mar-10-22 04:15PM
Feb-28-22 06:03AM
Feb-24-22 01:32PM
Feb-22-22 07:35AM
06:15AM
Feb-20-22 08:44PM
Feb-18-22 02:34AM
Feb-17-22 04:15PM
Feb-08-22 09:38AM
Feb-07-22 08:38PM
Feb-06-22 04:25PM
Jan-27-22 01:38PM
Jan-25-22 12:10PM
Jan-13-22 07:20AM
Jan-12-22 07:00AM
Jan-05-22 04:15PM
Dec-31-21 07:32AM
12:01AM
Dec-27-21 09:38PM
09:38PM
Dec-25-21 02:38PM
Dec-23-21 05:38PM
07:38AM
Dec-21-21 02:38AM
Dec-20-21 02:07PM
Dec-17-21 09:38PM
05:38PM
04:38PM
Dec-14-21 11:38PM
Dec-11-21 05:38AM
Dec-08-21 07:38PM
07:38PM
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; and clinical research services, including biostatistics, clinical operations, clinical supplies management, covid-19, data management, decentralized & hybrid clinical solutions, endpoint adjudication services, interactive response technologies, investigator payments, medical affairs, medical writing and publishing, pharmacovigilance, and site and patient solutions. The company also provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. In addition, it offers commercial positioning, early phase, language, medical imaging, and strategic solutions, as well as clinical trial management, consulting, and contract staffing services. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.